Skip to main content

Table 1 Basic characteristics of patients with acquired VEN-R AML in our cohort

From: Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia

Characteristics Value
Patients (N) 9
Male/Female (N) 5/4
Age (year) 73 (68–78)
De novo/Secondary (N) 8/1
FAB: M0/M1/M4/M5 (N) 2/1/3/3
Karyotype: normal/abnormal (N) 4/5
Bone marrow blast at venetoclax initiation (%) 62 (23–92)
Molecular feature at venetoclax initiation (N)
AML1-ETO 1
NPM1 mutation 3
FLT3-ITD 4
DNMT3A mutation 4
TP53 mutation 1
ASXL1 mutation 2
RUNX1 mutation 2
Bone marrow blast at venetoclax resistance (%) 10.5 (6–74)
Molecular feature at venetoclax resistance (N)
AML1-ETO 1
NPM1 mutation 2
FLT3-ITD 3
DNMT3A mutation 3
TP53 mutation 2
ASXL1 mutation 2
RUNX1 mutation 1
Cycles from venetoclax initiation to resistance (N) 3 (3–15)